James J. Dignam, Linda Colangelo, Wei Tian, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001
Reviewers: Li Liu, MD
Source: Journal of the National Cancer Institute, 91(22): 1933-1940, November 1999
Some retrospective studies have reported poorer outcomes from colon cancer among African-Americans compared to Caucasian Americans. The cause of this disparity may be multifactorial, including diagnosis at later disease stage, unfavorable disease features, differences in treatment, and socioeconomic factors. Dignam and colleagues examined survival and related outcomes after treatment of primary colon cancer among African-American and Caucasian patients participating in randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP).
The review was based on data from 5,969 white patients and 663 black patients enrolled in five NSABP clinical trials from 1977 through 1994.
Survival rates in the general population who have colon cancer tend to be lower for African Americans than Caucasians. The difference is considerably less for African Americans and Caucasians entered in clinical trials. Higher mortality rates for chronic diseases other than cancer may contribute to the shorter overall survival times among African Americans.
Apr 4, 2012 - Adding cetuximab to adjuvant chemotherapy does not improve disease-free survival in stage III colon cancer patients following surgical resection, according to a study published in the April 4 issue of the Journal of the American Medical Association.
Mar 24, 2010
May 29, 2014